By affecting the production of IL-1beta [46], ApoA-I may be useful in the treatment of infectious diseases, including COVID-19, which is manifested by increased levels of IL-6, TNF, and IL-1beta [47]. The gene discussed is IL1B; the disease is COVID-19.